Pharmacokinetic Study of MIN-101 in Healthy Subjects
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess how MIN-101 is taken up by the body when given in different
amounts and in different formulations. The drug will be given as a single dose in Part 1 of
the study and during Part 2 of the study as multiple dose, once daily for 7 days. The
ultimate aim is to find an optimal formulation which can be developed as a once daily dose
for the treatment of schizophrenia.